EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Implementation Science for Effective Risk Management of Medicines: A Call for Global Action

Meredith Y Smith, Priya Bahri, Delese Mimi Darko, Alex N O Dodoo, Adrien Inoubli, Elaine H Morrato, Christine Perera, Shanti Pal

Drug Safety · 30.07.2026

DOI: 10.1007/s40264-026-01702-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Safety, online erschienen am 30.07.2026. Verfasst von Meredith Y Smith und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California, Los Angeles, USA. meredithysmith1@gmail.com. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: World Health Organization, University of Southern California.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmaceutical risk minimization, as an essential element of pharmacovigilance, aims to reduce medicinal product risks in order to improve a product’s benefit-risk profile. However, to date the practical application of risk minimization has proved challenging. In particular, risk minimization standards developed by and for high-income countries have been shown to have limited suitability in low and middle income countries (LMICs) and high-income countries have struggled to deliver these programs with consistently high quality and demonstrable long-term impact. The World Health Organization’s new 2025 framework for pharmacovigilance—‘The Global Smart Pharmacovigilance Strategy’—calls for developing comprehensive and sustainable safety monitoring and risk management practices as integral components of healthcare and regulatory systems in all member countries globally. The field of implementation science offers a robust set of approaches to address current gaps and challenges in risk minimization, one that can help meet the needs of twenty-first century pharmacovigilance. We call for the convening of an internationally representative expert forum to develop a pragmatic framework and set of recommendations regarding the application of implementation science good practices to advance risk minimization for medicinal products globally. The framework and recommendations should be practical, sustainable and equally applicable for use in LMIC and high-income countries. In addition, the framework and recommendations should be accompanied by a blueprint for implementation science capacity building as well as a dissemination plan for promoting uptake of the framework and recommendations by industry and regulatory authorities worldwide.

Autor:innen und Institutionen

  • University of Southern California, Los Angeles, USA. meredithysmith1@gmail.com.
  • , New London, United States. meredithysmith1@gmail.com.
  • European Medicines Agency, Amsterdam, The Netherlands.
  • African Medicines Agency, Kigali, Rwanda.
  • World Health Organization-Regional Office South-East Asia, New Delhi, India.
  • Loyola University Chicago, Chicago, USA.

Förderung

  • World Health Organization
  • University of Southern California

Zitieren

APA

Smith, M. Y., Bahri, P., Darko, D. M., Dodoo, A. N. O., Inoubli, A., Morrato, E. H., Perera, C., & Pal, S. (2026). Implementation Science for Effective Risk Management of Medicines: A Call for Global Action. Drug Safety. https://doi.org/10.1007/s40264-026-01702-5

Vancouver

Smith MY, Bahri P, Darko DM, Dodoo ANO, Inoubli A, Morrato EH, et al. Implementation Science for Effective Risk Management of Medicines: A Call for Global Action. Drug Safety. 2026. doi:10.1007/s40264-026-01702-5

BibTeX
@article{Smith2026,
  author = {Smith, Meredith Y and Bahri, Priya and Darko, Delese Mimi and Dodoo, Alex N O and Inoubli, Adrien and Morrato, Elaine H and Perera, Christine and Pal, Shanti},
  title = {Implementation Science for Effective Risk Management of Medicines: A Call for Global Action},
  journal = {Drug Safety},
  year = {2026},
  doi = {10.1007/s40264-026-01702-5}
}
Kostenlos starten →